Dian Diagnostics Group Co. Ltd. Class A

Dian Diagnostics Group Co. Ltd. Class A

SSZSE:300244
19.24
CNY
-0.45
(-2.29%)
0.97EPS
26.71P/E
12.82BMarket Cap
Apr 09Next Earn
Dian Diagnostics Group Co. Ltd. Class A
SZSE:300244
(Shenzhen Stock Exchange)

Recent

price

19.24

P/E

ratio

26.71

div

yld

2.44%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.01
1.19
1.48
2.12
2.8
3.83
6.99
9.16
12.73
13.63
17.16
21.09
32.56
21.45
19.77
16.52
16.26
Revenue per Share
0.1
0.1
0.13
0.18
0.26
0.36
0.48
0.64
0.71
0.56
1.29
1.87
2.3
0.49
-0.58
0.07
0.77
Basic EPS, GAAP
0.07
-0.01
-0.04
0.06
-0.02
-0.05
-0.34
-0.63
-0.15
0.12
1.73
1.17
1.11
1.95
1.37
2.85
- -
Free Cash Flow per Basic Share
- -
- -
0.04
0.02
0.05
0.08
0.11
0.16
0.32
0.37
0.42
0.43
0.48
0.48
0.93
0.42
0.47
Dividend per Share
0.43
0.98
1.07
1.21
1.42
1.91
3.79
4.27
6.69
6.42
7.57
9.42
11.88
12.07
10.5
10.31
10.75
Book Value per Share
0.42
0.97
1.01
1.13
1.33
1.34
1.04
1.36
3.24
3.56
5.4
7.28
10.48
10.6
9.66
9.6
9.69
Tangible Book Value per Share
339
404
479
480
477
486
547
546
547
620
620
620
623
625
617
611
611
Basic Weighted Avg Shares
343
482
706
1,015
1,335
1,858
3,824
5,004
6,967
8,453
10,649
13,083
20,282
13,408
12,196
10,096
9,939
Sales/Revenue/Turnover
10.18
8.85
9.66
10.72
11.09
10.47
10.85
11.12
13.28
12.83
18.92
17.43
20.06
11.07
8.42
7.34
8.9
Operating Margin (%)
7
9
13
20
27
38
61
117
177
248
293
495
799
691
609
456
- -
Depreciation Expense
32
42
60
86
125
175
263
350
389
347
803
1,163
1,434
307
-357
44
469
Net Income, GAAP
20.99
15.12
18.93
19.36
16.06
15.05
22.19
26.27
19.84
25.36
18.78
17.16
26.78
27.15
- -
43.16
25.15
Effective Tax Rate (%)
9.44
8.75
8.52
8.48
9.33
9.41
6.87
6.99
5.58
4.11
7.54
8.89
7.07
2.29
-2.93
0.44
4.72
Profit Margin (%)
120
429
399
415
401
3
693
1,063
1,961
2,427
2,429
4,212
9,041
8,911
7,221
6,775
6,446
Working Capital
1
- -
- -
- -
- -
80
1,076
1,920
1,181
1,064
896
1,196
3,285
2,620
1,786
1,147
635
LT Debt
160
477
527
590
702
1,059
2,546
2,947
4,715
5,138
6,029
7,476
9,502
9,905
8,767
8,604
8,839
Total Equity
16.54
11.98
11.51
15.08
17.19
12.71
10.61
8.37
7.99
6.85
11.49
13.84
15.22
4.28
- -
1.52
- -
Return on Invested Capital (%)
22.65
13.25
12.49
14.66
16.81
14.83
7.21
6.14
4.52
3.36
7.54
9.39
8.82
1.46
- -
0.29
- -
Return on Capital (%)
25.21
13.7
12.37
15.86
19.77
21.7
17.43
15.75
12.87
9.05
18.5
22.07
21.58
4.1
-5.06
0.68
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,527
1,463
896
LT Borrowings
819
628
518
LT Finance Leases
129
123
117
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
625
625
625
Market Capitalization
11,537
11,712
12,825

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
10,591
10,370
10,091
Cash, Cash Equivalents & STI
2,130
1,933
1,527
Accounts Receivable, Net
6,035
6,040
6,124
Inventories
1,445
1,417
1,521
Total Current Liabilities
3,874
3,901
3,645
Payables & Accruals
- -
- -
- -
ST Debt
1,527
1,463
896
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
28.45%
8.4%
-1.86%
Free Cash Flow
201.85%
22.99%
106.47%
Net Income, GAAP
-12.38%
-67.79%
-112.33%
Sales/Revenue/Turnover
24.09%
3.55%
-17.22%
Total Cash Common Dividend
29.23%
10.1%
-55.57%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,973
3,245
3,040
2,938
12,196
2025
2,365
2,571
- -
2,530
10,096
2026
2,247
2,526
2,635
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.08
0.1
-0.8
-0.58
2025
-0.03
0.05
- -
-0.02
0.07
2026
0.11
0.27
0.41
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.11
0.73
0.02
0.93
2025
0.06
0.28
- -
0.02
0.42
2026
0.05
0.37
0.04
- -
- -
Business
Dian Diagnostics Group Co., Ltd. Dian Diagnostics Group Co., Ltd. (300244.SZ) operates as a leading provider of integrated medical diagnostics solutions in China, with independent third-party diagnostic services as its core business. The company offers a comprehensive range of products and services, including medical diagnostic services across more than 4,000 parameters; diagnostic technology research and development in genomics, proteinomics, and metabolomics; production and sales of in vitro diagnostic reagents, equipment, laboratory supplies, and kits; molecular diagnosis, pathological diagnosis, and mass spectrometry diagnosis product lines; AI-assisted digital pathology solutions with digital slide scanners and real-time PCR systems; LC-MS/MS and DP-TOF nucleic acid mass spectrometry solutions; forensic drug testing and appraisal services; health management and diagnosis-treatment industrial chain integration; contract research organization (CRO) services; and cold chain logistics, supply chain optimization, and laboratory quality management. Dian Diagnostics Group Co., Ltd. serves over 22,000 medical institutions, including general hospitals, specialty hospitals, community health centers, physical examination centers, and disease control centers, having processed samples for more than 330 million people through its network of over 40 chain medical laboratories, 10 forensic science centers, and 4 health management centers; it operates primarily in China with recent international expansion. Founded in 1996 and headquartered in Hangzhou, Zhejiang Province, China, the company listed on the Shenzhen Stock Exchange in July 2011 and employs over 10,000 people. Recent developments include the establishment of DIAN Laboratory Co., Ltd. in Ho Chi Minh City, Vietnam, in November 2023 to advance global expansion with its "service + product" model; a strategic AI health management cooperation agreement with Huawei Cloud signed in 2024; a letter of intent for cooperation with Gulf Medical University in January 2024; increased investments in AI layout and bad debt reduction through negotiation and litigation announced in 2025; and ongoing collaborations in personalized cancer care and strategic alliances with tech firms for enhanced diagnostic capabilities since 2023.